Cellectar Biosciences to Host Conference Call on May 12th to Discuss First Quarter 2015 Results and Provide Update on Develop...
05 Mai 2015 - 2:30PM
Cellectar Biosciences, Inc. (Nasdaq:CLRB), a clinical stage
biopharmaceutical company developing innovative agents for the
detection and treatment of cancer, announced that management will
host a conference call and live webcast to discuss first quarter
2015 financial results and provide an update on each of its
development programs on Tuesday, May 12th at 5:00 PM EDT.
Event Details:
Interested investors may participate in the conference call by
dialing 888-646-8293 (domestic) or 973-453-3065 (international).
Participants may also access both the live and archived webcast of
the conference call on the investor relations section of
Cellectar's web site, www.cellectar.com.
To Ask Questions:
Following prepared remarks and time permitting, management will
provide an opportunity for participants dialed into the live
teleconference to ask questions. Investors may also e-mail their
questions to ir@cellectar.com. E-mail questions will be accepted
until 12:00 noon ET on Tuesday, May 12th, 2015.
About Cellectar Biosciences, Inc.
Cellectar Biosciences is developing agents to detect, treat and
monitor a broad spectrum of cancers. Using a novel phospholipid
ether analog (PLE) platform technology as a targeted delivery and
retention vehicle, Cellectar's compounds are designed to be
selectively taken up and retained in cancer cells including cancer
stem cells. With the ability to attach both imaging and therapeutic
agents to its proprietary delivery platform, Cellectar has
developed a portfolio of product candidates engineered to leverage
the unique characteristics of cancer cells to "find, treat and
follow" malignancies in a highly selective way. I-124-CLR1404 is a
small-molecule, broad-spectrum, cancer-targeted PET imaging agent
currently being evaluated in a Phase II glioblastoma imaging trial.
Additionally, multiple investigator-sponsored Phase I/II clinical
trials are ongoing across 11 solid tumor
indications. I-131-CLR1404 is a small-molecule,
broad-spectrum, cancer-targeted molecular radiotherapeutic that
delivers cytotoxic radiation directly and selectively to cancer
cells including cancer stem cells. A Phase Ib dose-escalation
trial of I-131-CLR1404 in patients with advanced solid tumors was
completed in the first quarter of 2014 and results presented at the
American Society of Clinical Oncology (ASCO) 2014 Annual
Meeting. CLR1502 is a preclinical, cancer-targeted,
non-radioactive optical imaging agent for intraoperative tumor
margin illumination and non-invasive tumor imaging. For additional
information please visit www.cellectar.com.
This news release contains forward-looking statements. You
can identify these statements by our use of words such as "may,"
"expect," "believe," "anticipate," "intend," "could," "estimate,"
"continue," "plans," or their negatives or cognates.
These statements are only estimates and predictions and are subject
to known and unknown risks and uncertainties that may cause actual
future experience and results to differ materially from the
statements made. These statements are based on our current
beliefs and expectations as to such future outcomes. Drug
discovery and development involve a high degree of risk.
Factors that might cause such a material difference include, among
others, uncertainties related to the ability to raise additional
capital, uncertainties related to the ability to attract and retain
partners for our technologies, the identification of lead
compounds, the successful preclinical development thereof, the
completion of clinical trials, the FDA review process and other
government regulation, our pharmaceutical collaborators'
ability to successfully develop and commercialize drug candidates,
competition from other pharmaceutical companies, product pricing
and third-party reimbursement. A complete description of risks and
uncertainties related to our business is contained in our periodic
reports filed with the Securities and Exchange Commission including
our Form 10-K for the year ended December 31, 2014. These
forward-looking statements are made only as of the date hereof, and
we disclaim any obligation to update any such forward-looking
statements.
CONTACT: INVESTOR CONTACT
Kate McNeil,
Vice President of IR, PR & Corporate Communications
Cellectar Biosciences, Inc.
Phone: (347) 204-4226
Email: kmcneil@cellectar.com
Cellectar Biosciences (NASDAQ:CLRBW)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Cellectar Biosciences (NASDAQ:CLRBW)
Historical Stock Chart
Von Jul 2023 bis Jul 2024